This study is testing an experimental drug called REGN13335 for adults with Pulmonary Arterial Hypertension (PAH), a condition where blood pressure in the arteries of the lungs is too high. The goal is to see how safe and effective REGN13335 is when taken with your current PAH medications. Researchers will also look at potential side effects and how your body processes REGN13335. You may be able to join if you have a documented diagnosis of PAH, are in WHO functional class II or III, and are on a stable dose of other PAH treatments. The main way success will be measured is by looking at changes in your Pulmonary Vascular Resistance (PVR) after 24 weeks. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 99 participants and will compare REGN13335 to a placebo (an inactive substance).

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at week 24, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.